Posted by Michael Wonder on 11 Jun 2020
Health economic assessment of Waylivra in familial chylomicronaemia
11 June 2020 - TLV has made a health economic assessment to the regions of the drug Waylivra (volansorsen).
Waylivra is a supplement to diet therapy for adult patients with genetically confirmed familial chylomicronaemia and high risk of pancreatitis when diet and triglyceride-lowering therapy have not had sufficient effect.
TLV considers that there are very high uncertainties in the clinical evidence that the company has included in the health economic analysis, so TLV adjusts a number of assumptions. In TLV's basic scenario, the cost per quality-adjusted life year amounts to approximately SEK 7.6 million.
